机译:HER2相关生物标志物(HER2,P95HER2,HER3,PTEN和PIK3CA)的作用在Lapatinib Plus Capecitabine在HER2阳性晚期乳腺癌难治性对Trastuzumab的疗效
Kumamoto Shinto Gen Hosp Dept Breast Oncol Kumamoto Japan;
Kurume Univ Sch Med Dept Surg Kurume Fukuoka Japan;
JCHO Kurume Gen Hosp Dept Breast Surg Kurume Fukuoka Japan;
Kitakyushu Municipal Med Ctr Dept Surg Kitakyushu Fukuoka Japan;
Kumamoto City Hosp Dept Breast &
Endocrine Surg Kumamoto Japan;
Saitama Red Cross Hosp Dept Breast Surg Saitama Japan;
Fukuoka Univ Dept Internal Med Div Oncol Hematol &
Infect Dis Fukuoka Japan;
Sagara Hosp Breast Surg Oncol Kagoshima Japan;
Shimada Breast Clin Kitakyushu Fukuoka Japan;
Isesaki City Hosp Dept Surg Isesaki Japan;
Hirose Hosp Dept Breast Surg Fukuoka Japan;
Urasoe Gen Hosp Dept Breast Surg Urasoe Japan;
Saiseikai Yokohamashi Nanbu Hosp Dept Surg Yokohama Kanagawa Japan;
Natl Hosp Org Kokura Med Ctr Dept Surg Kitakyushu Fukuoka Japan;
Ueo Breast Canc Hosp Dept Breast Surg Oita Japan;
Sagara Hosp Dept Pathol Kagoshima Japan;
Kitakyushu Municipal Med Ctr Dept Pathol Kitakyushu Fukuoka Japan;
Kumamoto Shinto Gen Hosp Dept Pathol Kumamoto Japan;
Kitakyushu Municipal Med Ctr Dept Surg Kitakyushu Fukuoka Japan;
Fukuoka Univ Sch Med Gen Med Res Ctr Fukuoka Japan;
Breast cancer; Human epidermal growth factor receptor 2; Lapatinib; p95HER2; Trastuzumab;
机译:HER2相关生物标志物(HER2,P95HER2,HER3,PTEN和PIK3CA)的作用在Lapatinib Plus Capecitabine在HER2阳性晚期乳腺癌难治性对Trastuzumab的疗效
机译:拉帕替尼联合卡培他滨治疗HER2阳性晚期或转移性乳腺癌患者的疗效,安全性,药代动力学和生物标志物研究:来自51位日本患者的临床研究结果
机译:在以前用Trastuzumab和化疗以前治疗的Her2阳性晚期乳腺癌的患者中,Capecitabine和Lapatinib的随机阶段II试验,患有IMC-A12(Cituxumumab):NCCTG N0733(联盟)
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:肠道微生物群和胸瘤反应在Her2阳性乳腺癌中
机译:在曲妥珠单抗治疗后接受拉帕替尼治疗的HER2阳性晚期乳腺癌患者中定量HER2HER3和p95HER2水平的预测价值
机译:在曲妥珠替纳布进展后,在曲妥替尼替税后治疗HER2阳性晚期乳腺癌患者的定量HER2,HER3和P95HEH2水平的预测值